Abstract
Study Objective. To determine the impact of nesiritide on health care resource utilization and complications in patients hospitalized with decompensated heart failure. Design. Retrospective case-control study. Setting. United States hospitals. Patients. Two hundred sixteen patients hospitalized for decompensated heart failure. Measurements and Main Results. One hundred eight patients who received a nesiritide infusion for a minimum of 12 hours during the first 48 hours after hospital admission were matched with 108 patients not receiving nesiritide. Health care resource utilization, consisting of hospital length of stay (LOS), rate of rehospitalization within 90 days, concomitant drugs administered, and laboratory and diagnostic tests, was determined for each hospital admission. Rates of adverse events also were recorded. Patients receiving nesiritide had a significantly shorter LOS in a critical care unit (p=0.03). General medical ward or step-down unit LOS was not different between the treatment groups. A favorable trend toward a lower rate of rehospitalization over the 90-day follow-up period was observed with nesiritide (p=0.07). The number of patients who developed life-threatening ventricular arrhythmias and hypotension was similar for both treatment groups. However, in patients receiving nesiritide, significantly less atrial fibrillation (p=0.03) and renal dysfunction (p=0.04) occurred compared with patients not receiving nesiritide. Conclusion. Nesiritide therapy is associated with significant reductions in both health care resource utilization and complications in patients with decompensated heart failure.
| Original language | English |
|---|---|
| Pages (from-to) | 1137-1146 |
| Number of pages | 10 |
| Journal | Pharmacotherapy |
| Volume | 24 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 4 2004 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure. / Lenz, Thomas L.; Foral, Pamela A.; Malesker, Mark A.; Hunter, Claire B.; Hilleman, Daniel E.
In: Pharmacotherapy, Vol. 24, No. 9, 04.09.2004, p. 1137-1146.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure
AU - Lenz, Thomas L.
AU - Foral, Pamela A.
AU - Malesker, Mark A.
AU - Hunter, Claire B.
AU - Hilleman, Daniel E.
PY - 2004/9/4
Y1 - 2004/9/4
N2 - Study Objective. To determine the impact of nesiritide on health care resource utilization and complications in patients hospitalized with decompensated heart failure. Design. Retrospective case-control study. Setting. United States hospitals. Patients. Two hundred sixteen patients hospitalized for decompensated heart failure. Measurements and Main Results. One hundred eight patients who received a nesiritide infusion for a minimum of 12 hours during the first 48 hours after hospital admission were matched with 108 patients not receiving nesiritide. Health care resource utilization, consisting of hospital length of stay (LOS), rate of rehospitalization within 90 days, concomitant drugs administered, and laboratory and diagnostic tests, was determined for each hospital admission. Rates of adverse events also were recorded. Patients receiving nesiritide had a significantly shorter LOS in a critical care unit (p=0.03). General medical ward or step-down unit LOS was not different between the treatment groups. A favorable trend toward a lower rate of rehospitalization over the 90-day follow-up period was observed with nesiritide (p=0.07). The number of patients who developed life-threatening ventricular arrhythmias and hypotension was similar for both treatment groups. However, in patients receiving nesiritide, significantly less atrial fibrillation (p=0.03) and renal dysfunction (p=0.04) occurred compared with patients not receiving nesiritide. Conclusion. Nesiritide therapy is associated with significant reductions in both health care resource utilization and complications in patients with decompensated heart failure.
AB - Study Objective. To determine the impact of nesiritide on health care resource utilization and complications in patients hospitalized with decompensated heart failure. Design. Retrospective case-control study. Setting. United States hospitals. Patients. Two hundred sixteen patients hospitalized for decompensated heart failure. Measurements and Main Results. One hundred eight patients who received a nesiritide infusion for a minimum of 12 hours during the first 48 hours after hospital admission were matched with 108 patients not receiving nesiritide. Health care resource utilization, consisting of hospital length of stay (LOS), rate of rehospitalization within 90 days, concomitant drugs administered, and laboratory and diagnostic tests, was determined for each hospital admission. Rates of adverse events also were recorded. Patients receiving nesiritide had a significantly shorter LOS in a critical care unit (p=0.03). General medical ward or step-down unit LOS was not different between the treatment groups. A favorable trend toward a lower rate of rehospitalization over the 90-day follow-up period was observed with nesiritide (p=0.07). The number of patients who developed life-threatening ventricular arrhythmias and hypotension was similar for both treatment groups. However, in patients receiving nesiritide, significantly less atrial fibrillation (p=0.03) and renal dysfunction (p=0.04) occurred compared with patients not receiving nesiritide. Conclusion. Nesiritide therapy is associated with significant reductions in both health care resource utilization and complications in patients with decompensated heart failure.
UR - http://www.scopus.com/inward/record.url?scp=4344612205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4344612205&partnerID=8YFLogxK
U2 - 10.1592/phco.24.13.1137.38081
DO - 10.1592/phco.24.13.1137.38081
M3 - Article
C2 - 15460174
AN - SCOPUS:4344612205
VL - 24
SP - 1137
EP - 1146
JO - Pharmacotherapy
JF - Pharmacotherapy
SN - 0277-0008
IS - 9
ER -